首页> 美国卫生研究院文献>Cancer Communications >Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers
【2h】

Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers

机译:鼻咽癌患者血浆microRNA分析显示miR-548q和miR-483-5p是潜在的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs), which play a role in tumorigenesis, may also serve as diagnostic or prognostic biomarkers. However, studies on human miRNA profiles in plasma from nasopharyngeal carcinoma (NPC) patients are in their infancy. Here, we used microarrays to perform systematic profiling of human miRNAs in plasma from NPC patients. We subsequently used real-time quantitative polymerase chain reaction (Q-PCR) to validate miRNAs with aberrant expression that could serve as potential biomarkers. By comparing the plasma miRNA profiles of 31 NPC patients and 19 controls, 39 of 887 human miRNAs were found to be aberrantly expressed. Considering the fold change and P value, miR-548q and miR-483-5p were validated in 132 samples from 82 NPC patients and 50 controls. Moreover, high expression of miR-548q and miR-483-5p was further found in 3 NPC cell lines and clinical biopsy tissues from 54 NPC patients and 22 controls. Our results revealed that miR-548q and miR-483-5p are potential biomarkers of NPC. Combining the receiver operating characteristic (ROC) analyses of these 2 miRNAs, an area under the ROC curve (AUC) of 0.737 with 67.1% sensitivity and 68.0% specificity were obtained, showing the preliminary diagnostic value of plasma miRNAs. Moreover, most NPC patients with a poor outcome exhibited high expression (> median) of miR-548q (70.6%) and miR-483-5p (64.7%) in tissue samples, indicating their prognostic value. The high expression levels of miR-548q and miR-483-5p in plasma, cell lines, and clinical tissues of NPC patients indicate that their roles in NPC should be explored in the future.
机译:在肿瘤发生中起作用的MicroRNA(miRNA)也可以用作诊断或预后生物标志物。但是,有关鼻咽癌(NPC)患者血浆中人miRNA谱的研究尚处于婴儿期。在这里,我们使用微阵列对来自NPC患者的血浆中的人类miRNA进行系统分析。随后,我们使用实时定量聚合酶链反应(Q-PCR)验证了表达异常的miRNA,可以用作潜在的生物标记。通过比较31名NPC患者和19名对照的血浆miRNA谱,发现887个人中的39种miRNA异常表达。考虑到倍数变化和P值,在82位NPC患者和50位对照的132个样本中验证了miR-548q和miR-483-5p。此外,在54例NPC患者和22例对照的3种NPC细胞系和临床活检组织中进一步发现了miR-548q和miR-483-5p的高表达。我们的结果表明,miR-548q和miR-483-5p是NPC的潜在生物标志物。结合这两个miRNA的受体工作特征(ROC)分析,获得的ROC曲线下面积(AUC)为0.737,灵敏度为67.1%,特异性为68.0%,显示了血浆miRNA的初步诊断价值。此外,大多数不良结局的NPC患者表现出 miR - 548q (70.6%)和 miR - 483 - 5p (64.7%),表明它们的预后价值。 miR - 548q miR - 483 - 5p 的高表达水平鼻咽癌患者的血浆,细胞系和临床组织表明,它们在鼻咽癌中的作用应在未来进行探讨。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号